This study aimed to describe the occurrence and to evaluate the predictive factors of thrombocytopenia caused by parenteral linezolid in hospitalised patients without haemato-oncologic diseases. Using electronic medical records, a retrospective Baseline platelet count less than 150 × 10 3 /mm 3 was an independent predictor of early-onset (≤6 days) thrombocytopenia (adjusted OR, 5.07; 95% CI, 1.46-17.58; P = 0.011). Closer monitoring of platelet count is required in patients who receive parenteral linezolid therapy for 7 days or more, and have low baseline platelet counts or impaired renal function.
| INTRODUCTION
Linezolid, an oxazolidinone antibiotic, is indicated for the treatment of infectious diseases and has become widely used with the increasing prevalence of multidrug-resistant gram-positive bacteria. 1 Linezolid-induced thrombocytopenia is an important side effect to be considered when assessing the safe use of this medication 2, 3 and the associated risks of gastrointestinal and intracranial haemorrhage, and thus, mortality. 4, 5 While establishing appropriate measures to improve clinical outcomes for the patients are essential tasks for clinicians, published studies reporting the incidence and predictive factors for linezolid-induced thrombocytopenia had been insufficient and often limited due to the variabilities of the study design and patient population. Most studies included patients with haemato-oncologic diseases without distinguishing subgroups or disease severity 2, [6] [7] [8] [9] as the presence of haemato-oncologic diseases or variable status of myelosuppression can be a significant confounder in the evaluation of thrombocytopenia. Moreover, a number of studies included patients with a baseline platelet count of <100 × 10 3 /mm 3 in their populations, 2, 6, 8, 9 indicating that these patients already had thrombocytopenia. A number of published studies from countries from Asia and other Western countries investigating the incidence and risk factors for linezolid-induced thrombocytopenia have shown considerable interstudy variation in their findings, 2, 6, [8] [9] [10] [11] [12] and no published studies were found from Korea. In addition, considering the possibility of genetic associations of linezolid-induced thrombocytopenia, 13, 14 the results of published studies may be not applicable to Korean patients. Therefore, this study aimed to describe the timeline and clinical characteristics of linezolid-induced thrombocytopenia and to determine the risk factors among hospitalised patients in Korea, excluding those with haemato-oncologic diseases.
| MATERIALS AND METHODS

| Study design and patient population
This was a retrospective, longitudinal study using data extracted from the electronic medical records at Seoul National University Hospital in Korea from January 2005 to June 2016. Patients receiving ≥3 doses of parenteral linezolid every 12 hours and aged ≥19 years were included in the study. Patients diagnosed with haemato-oncologic diseases or myelosuppression were excluded. Within 1 week prior to the initiation of linezolid therapy, patients who had a history of platelet counts <100 × 10 3 /mm 3 or received platelet transfusions were also excluded. A sample size of 240 patients was calculated to be adequate in order to detect 20% difference in the incidence of thrombocytopenia with 80% power and 5% α-error based on a published study 9 using the MedCalc Statistical Software version 17.1 (MedCalc Software bvba, Ostend, Belgium). In addition, the rule that the number of participants should be at least 10 times more than the number of independent variables was also applied to determine the sample size using multivariate logistic regression. 15 
| Data collection and definition of thrombocytopenia
Demographic and clinical data of each patient were collected. Clinical information included body-weight, indication and duration of linezolid therapy, microbiological isolates, concurrent medications and laboratory data including platelet count, haemoglobin level, serum albumin and total bilirubin level for hepatic function, and serum creatinine level for renal function. All baseline laboratory data were collected between 7 days prior to initiating and the first day of linezolid therapy; the platelet count data were also collected from day 1 of the therapy until 30 days after the last dose, discharge or death. Thrombocytopenia was defined as a decrease in platelet count to <100 × 10 3 /mm 3 , based on guidelines from the National Institute of Allergy and Infectious Diseases. 16 Earlyonset thrombocytopenia was defined as the occurrence of thrombocytopenia within 6 days of initiating linezolid therapy. Baseline levels of platelets, haemoglobin, serum albumin and total bilirubin were categorised by the cut-off values of 150 × 10 3 /mm 3 , 10.5 g/dL, 3.0 g/dL and 2.0 mg/ dL, respectively. 16 The patient renal function was classified into 3 categories based on creatinine clearance (CLcr) calculated from serum creatinine level using the Cockcroft- 
| Statistical analysis
Descriptive statistics were used to summarise the demographic and clinical characteristics of the study population. Univariate and multivariate logistic regressions were used to evaluate the associations between the independent variables (ie, age, sex, weight, duration of linezolid therapy, baseline laboratory data and concurrent medications related to the risk of thrombocytopenia) and linezolid-induced thrombocytopenia. Logistic regression analyses were also used to assess the associations between the independent variables and early-onset thrombocytopenia. The odds ratios (ORs) and corresponding 95% confidence intervals (CI) were reported. The cumulative incidence of thrombocytopenia, stratified by the independent variables, was compared using a log-rank test and presented using Kaplan-Meier curves. The significance level was set at P < 0.05. Data analysis was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). The study protocol was approved by the Institutional Review Board (IRB) of Seoul National University Hospital (IRB No. H-1607-180-779).
| RESULTS
| Demographic and clinical characteristics
A total of 1252 patients received parenteral linezolid therapy from January 2005 to June 2016. After excluding 741 patients with haemato-oncologic diseases or myelosuppression and 247 patients with pre-existing thrombocytopenia, remaining 264 patients were included in this study. The mean age of the patients was 63.4 (standard deviation [SD] 15.8) years, and women constituted 41.7% of the population (Table 1 ). The mean duration of linezolid therapy was 13.3 (SD 9.7) days. The most common microbiological isolate was methicillinresistant Staphylococcus aureus (37.1%), followed by vancomycin-resistant Enterococcus (28.0%). The leading indications for linezolid therapy were cardiovascular system infections (24.6%) and bone and joint infections (24.2%). Platelet counts were monitored more than once a week in all patients who received linezolid for longer than 2 weeks.
Thrombocytopenia occurred in 77 patients (29.2%) after initiation of linezolid therapy and the mean time of onset was 11.2 (SD 7.4) days. Among the patients with thrombocytopenia, 35 (45.5%) required platelet transfusions, and 32 (41.6%) required linezolid withdrawal due to thrombocytopenia. Out of 77 patients, 8 patients were excluded as they were transferred to other hospitals and 21 patients were excluded as they died before recovery. The remaining 48 patients were followed up on platelet counts and their platelet counts were recovered in 8.2 (SD 4.3) days after the last dose of linezolid therapy.
| Risk factors for linezolid-induced thrombocytopenia
While age, sex, and body-weight were not associated with the incidence of thrombocytopenia, receiving linezolid therapy for ≥7 days was associated with a higher risk of thrombocytopenia ( Table 2 ). The odds of linezolid-induced thrombocytopenia significantly increased when the duration of linezolid therapy was extended to ≥7 days (adjusted OR, 7.25, 19.51 and 28.80; 95% CI, 1.92-27.38, 4.76-79.95, 6.48-127.92 for 7-13 days, 14-20 days and ≥21 days, respectively; P < 0.01 for all values). Patients with a baseline platelet count of 100-149 × 10 3 /mm 3 showed an approximately 5 times higher incidence of thrombocytopenia than did those with a baseline platelet count of ≥150 × 10 3 / mm 3 (adjusted OR, 5.08; 95% CI, 2.06-12.55; P < 0.001).
Patients with a baseline CLcr of <30 mL/min were also significantly more likely to exhibit thrombocytopenia than were those with a baseline CLcr of ≥60 mL/min (adjusted OR, 4.19; 95% CI, 1.59-11.06; P = 0.004). No significant difference was observed in the thrombocytopenia incidence in relation to the other baseline levels, including haemoglobin, albumin and total bilirubin. Concurrent low-dose aspirin therapy (ie, ≤160 mg/d) 18 was associated with a higher risk of thrombocytopenia (adjusted OR, 2.99; 95% CI, 1.26-7.08; P = 0.013). No significant association was observed between linezolidinduced thrombocytopenia and other concurrent medications associated with the risk of thrombocytopenia, including amiodarone, carbapenem, ceftriaxone, digoxin, haloperidol, heparins, piperacillin/tazobactam, rifampin, sulfamethoxazole/trimethoprim, tacrolimus and valproic acid. Fluoroquinolones and caspofungin were not analysed because none of the patients used them concurrently.
Kaplan-Meier analysis also revealed a higher cumulative incidence of thrombocytopenia in patients with a baseline platelet count of 100-150 × 10 3 /mm 3 , CLcr of <30 mL/ min, or those receiving concurrent low-dose aspirin therapy than those who did not (Figure 1 ).
| Risk factors for early-onset thrombocytopenia
Only the baseline platelet counts of 100-149 × 10 3 /mm 3 were associated with a higher likelihood of early-onset 
| DISCUSSION
To the best of our knowledge, this is the first study assessing the incidence and risk factors for linezolid-induced thrombocytopenia in Korean patients. A particular strength of our study is that patients with haemato-oncologic diseases and existing thrombocytopenia, which could be confounding factors, were excluded from the study population. Findings from our study may help predict which patients are at risk of developing thrombocytopenia, formulate monitoring strategies in terms of timelines of the occurrence and recovery, and aid in the selection of alternative antimicrobials in the prevention of thrombocytopenia in patients without haemato-oncologic diseases. We found that the | 231 duration of linezolid therapy, baseline platelet counts, renal function and concurrent medication was associated with linezolid-induced thrombocytopenia in Korean patients without haemato-oncologic diseases. The cumulative incidence of 29.9% for linezolidinduced thrombocytopenia in this population is lower than that reported in several published studies (38.6%-48.4%) from Asian patients. [6] [7] [8] [9] Unlike our study, these studies included patients with haemato-oncologic diseases and defined thrombocytopenia as a reduction of >25%-30% from the baseline platelet count. Conversely, a cumulative incidence similar to that in our study was reported in Chinese (27.2%) 10 and Spanish studies (24.5%), 12 neither of which included patients with haemato-oncologic diseases or thrombocytopenia in their study populations. These studies also applied the same definition of thrombocytopenia as that used in our study. 10, 12 Our study adopted the cut-off value of <100 × 10 3 /mm 3 , which has been closely associated with an increased mortality rate and is a reference value for treatment decisions. 5, 19 In our study, most patients demonstrated recovery of platelet counts after discontinuation of linezolid therapy, which is consistent with the findings from a prospective study showing that linezolid-induced thrombocytopenia is reversibly improved by the discontinuation of therapy. 20 The duration of linezolid therapy was significantly associated with the incidence of thrombocytopenia, which is in line with the results of several published studies. However, the cut-off duration as a risk factor in our study was different from the results of other studies, where it ranged from 10 to 14 days. 7, 9, 10 Our study revealed that the incidence of thrombocytopenia among patients receiving linezolid therapy for ≥7 days was significantly higher than that among those receiving therapy for <7 days, and the incidence of thrombocytopenia increased in proportion to the duration of linezolid therapy by 7 days. Our findings showed that testing frequencies of the platelet counts followed the monitoring guidance listed on the approved package insert by the Ministry of Food and Drug Safety of South Korea, which is consistent with the guidance recommended by the U.S. FDA 21 in all patients who received linezolid for longer than 2 weeks. We believe the adherence of the monitoring guidance from the regulatory agency would adequately detect thrombocytopenia in the majority of the patients and even earlier monitoring may be indicated for selected patients who have baseline platelet counts of 100-150 × 10 3 /mm 3 , CLcr of <30 mL/min or those receiving concurrent low-dose aspirin therapy. Findings from our study indicate that a baseline platelet count of 100-149 × 10 3 /mm 3 was significantly associated with a higher likelihood of developing thrombocytopenia corroborated with reports from other studies. 2, 6, 10, 12 We found that a baseline platelet count of 100-149 × 10 3 /mm 3 was also significantly associated with a higher likelihood of early-onset thrombocytopenia. This finding is also in accordance with the result of the study by Hanai et al 8 showing that patients with early-onset thrombocytopenia had a significantly lower baseline platelet count than did those without. Our study indicated that decreased renal function was an influential factor for linezolid-induced thrombocytopenia, which was also in line with previously published studies. 8, 9, 22 The increased odds of thrombocytopenia in patients with renal dysfunction were explained by previous studies showing that the increased blood concentration of linezolid-induced by impaired renal function increases the risk of thrombocytopenia. 23, 24 However, the cut-off value of CLcr as a risk factor varied among studies as follows: <60 mL/min, 8 <50 mL/min 9 or <30 mL/min. 22 In our study, the incidence of thrombocytopenia was significantly higher in patients with a baseline CLcr of <30 mL/min than in those with a CLcr of ≥60 mL/min. Published studies investigating the risk of concurrent medications have shown that fluoroquinolones 9 and caspofungin 10 were influential factors for the development of linezolid-induced thrombocytopenia. In our study, the influence of these drugs could not be investigated because of the absence of patients who use them. In our study, lowdose aspirin use was significantly associated with a higher likelihood of linezolid-induced thrombocytopenia. Lowdose aspirin has antithrombotic properties, 25 producing an inhibitory effect on platelet aggregation, 26 and has been reported to cause drug-induced immune thrombocytopenia. 27 Our findings demonstrating the increased tendency of linezolid-induced thrombocytopenia in relation to lowdose aspirin therapy suggested a need for closer monitoring for thrombocytopenia occurrence during linezolid therapy. This study had several limitations. Firstly, because the study was retrospective in nature, we were unable to confirm the accuracy of the data or to ascertain missing data. Secondly, considering wide confidence intervals of odds ratio in some of the point estimates, the possibility of type 2 errors could not be excluded. Thirdly, although the study was conducted in the largest national hospital in Korea, which accommodates patients from across the country, it is a tertiary hospital and our results may not be generalisable to all Korean patients. However, our findings will be helpful in predicting the risk factors for the development of linezolidinduced thrombocytopenia and in the establishment of an appropriate drug utilisation strategy in linezolid therapy.
In conclusion, the incidence of linezolid-induced thrombocytopenia was approximately 30% among Korean patients without haemato-oncologic diseases. Close platelet count monitoring can potentially serve as a clinically meaningful follow-up activity for identifying thrombocytopenia while targeting the patients who receive linezolid therapy longer than a week with impaired renal function.
